Credits: Canva
Many of us may have taken ibuprofen, sometimes two pills at once, especially when we are struggling with menstrual cramps. Well, as good these pills may be in treating the pain, they are not recommended for your health, especially if you are someone who consumes it on a daily basis or frequently. Gastroenterologist Trisha Pasricha, MD, writes in The Washington Post about why should you avoid taking nonsteroidal anti-inflammatory drugs, or NSAIDs, such as ibuprofen, naproxen and aspirin.
She writes that NSAIDs are great in treating short term pain. They comprise of a group of drugs that inhibit the production of prostaglandins, which serve as a variety of purposes in the body. Some of which also includes contracting the uterus during menses and regulating blood flow in our vessels.
While one to two doses every now and then is okay, following a regular dosage routine, which could range from several times a month, or twice in an hour or so could lead to health risk. NSAIDs are well known to increase intestinal permeability. This means, these painkillers could damage the lining of your gut.
A 2018 review by Ingvar Bjarnason et. al., also writes about how NSAIDs can reduce the blood flow in the tiny vessels that feeds our guts. It can also disrupt the intestinal cells forming a barrier between the outside world and your insides.
While people with conditions like migraines, chronic back pain or bad period cramps can find NSAIDs to be helpful. It is always advisable to have a chat with your physicians to explore NSAID alternatives.
Pasricha suggests acetaminophen.
However, if someone is in dire need of NSAID, her tip is to take the pill right at the start of your symptoms. She says that the drug can do a far better job at stopping things at the source than chasing after all prostaglandins.
NSAIDs are available as over the counter drug, which means people do not need a prescription for it and can make medical decision about them without the guidance of a physician.
A 2018 study published in the Official Journal of the International Society for Pharmacoepidemiology by David W Kaufman, et.al., found that 15% of adult ibuprofen users in the US have exceeded the maximum recommended daily dose. The study also mentions that more than a third of ibuprofen users were taking other NSAIDs, like aspirin and naproxen, while consuming ibuprofen at the same time. Out of these, 61% did not realise that they were using NSAIDs.
Pasricha talks about how it ruptures the gut wall, as she herself has rushed to the hospital in the middle of the night "far more times than" she can count "to perform an emergency endoscopy on someone who was bleeding profusely from an ulcer caused by NSAID".
Another 2009 study published in the American Journal of Gastroenterology states that as many as 1 in 4 chronic NSAID users will get an ulcer and about 4% will bleed or rupture through the gut wall.
An older study from 2005 titled A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy, found that as 75 percent of people regularly using NSAIDs develop low-grade inflammation in their small bowels. NSAIDs can also lead to development of fatty liver disease. This happens because your gut lining becomes more permeable, more toxins and bacteria from the outside world enters your liver and leads to inflammation.
A 2011 study titled Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials, states that as many as 6% of people taking NSAIDs regularly have found their blood count dropping within a few months of starting the medicines, this suggests that this is due to the small, slow amount of bleeding in the gut overtime.
Credit: iStock
Nicotine pouches have become popular in the UK, show many studies, this is especially true in the case of young adults.
In fact, a new study done by the researches from University College London (UCL) has found that in the last five years, there has been an increase from 0.1 per cent to 1 per cent of adults using nicotine pouches. This means, around 522,000 more people in the UK have started using the pouches.
The pouches are placed between the lip and gum and it releases nicotine slowly. The pouches are also available in variety of flavors, with sweeteners and plant-based fibers. It does not contain tobacco like vapes do and usually are considered to be a healthier alternative to smoking.
Health and Me ran a fact check on whether it truly is safer than smoking, and here is what we found.
Are Nicotine Pouches Safer Than Smoking?
"This risks are substantially less than some other nicotine products like smoking, because there is no tobacco and there is no combustion," said Dr Harry Tattan-Birch, the lead author of the study, to Mornings with Ridge and Frost.
"And we know the combustion of tobacco is the thing that causes most of the diseases related to smoking," he says.
However, he and his team has warned that while it may not cause serious illness like tobacco can, young people could have a negative impact in their lungs and brains, as they are still in developing stage. This makes them more sensitive to the effects of nicotine, and it could become difficult to stop using it.
A UCL research fellow earlier told Sky News that while nicotine pouches are far less harmful than smoking, their long-term effects remain unclear because they are relatively new. Drawing on what is known about their contents, she noted they are not risk-free, as users are still exposed to some toxic substances, albeit at much lower levels.
Who Are Using These Nicotine Pouches?
Researchers from UCL, supported by Cancer Research UK, analysed survey responses from 127,793 people aged 16 and above across England, Scotland and Wales, collected between October 2020 and March 2025.
Their analysis showed that nicotine pouch use among 16 to 24-year-olds rose to 4% in 2025, up from just 0.7% in 2022. The increase was most pronounced among young men, with one in 13 men in this age group, or 7.5%, reporting use.
Overall, men accounted for 72% of nicotine pouch users between 2022 and 2025, while 47% were under the age of 25. Dr Tattan-Birch said the growth in use has been driven almost entirely by young people, particularly young men, with usage among adults over 35 remaining low and largely unchanged.
He added that this trend also includes children. Since nicotine pouches are not classified as tobacco or vape products, there are currently no age limits. Advertising is also unrestricted, allowing brightly coloured, sweet-flavoured products to appeal to younger audiences.
Do Nicotine Pouches Help Quit Smoking?
The research found that 69 per cent of pouch users were reported using other nicotine products, while 56 per cent of them smoked, as per the survey from January 2022 to March 2025.
1 in 6, which makes it 16 per cent said they never regularly smoked. "Whether nicotine pouches are good or bad for public health depends on who is using them. If it's a young person who would otherwise start smoking, then the use of pouches might help to reduce harm. However, if it's a person who otherwise would not use nicotine at all, then the potential for harm increases," said Tattan-Birch.
Credits: canva
A woman experiencing abdominal discomfort went to her gynecologist for an ultrasound, only to discover something far more startling than a baby. The mom, who shares her story on TikTok under the handle @sandwitchbread, revealed her medical surprise in a video that has now amassed over 1.9 million views. She said she had been struggling with pain and unusual bleeding since giving birth to her two-year-old son and decided to see a gynecologist fearing she might be pregnant again.
During the ultrasound, she noticed something on the screen, but the doctor quickly reassured her it wasn’t a baby. “When my doctor came in to share the results,” the TikToker recalled, “she looked me in the eyes and told me I had a seven-centimeter cyst, about the size of a chicken egg, called a dermoid cyst.”
A dermoid cyst is a pocket of tissue growth that can contain normal body tissues, sometimes including hair, fluid, teeth, or skin. While this TikToker’s cyst was in her uterus, dermoid cysts are most commonly found in the ovaries. They are generally harmless but often require surgical removal. According to the National Cancer Institute, dermoid cysts are present from birth but may not be detected until later in life. These benign tumors originate from embryonic cells that become “trapped” and develop into tissues in the wrong location. Teeth and hair are frequent components, and surgery is usually recommended if the cyst causes symptoms or complications.
Dermoid cysts develop hair and teeth because they arise from trapped embryonic cells (ectoderm) that can grow into skin, hair follicles, sweat glands, and even teeth, instead of forming the tissues normally found in the ovary or skin. Essentially, they are benign tumors made up of mature but misplaced body tissues from the outer layer of the embryo, which normally forms skin and related structures.
Most ovarian dermoid cysts remain symptom-free unless complications occur. When symptoms do appear, the most common one reported is lower abdominal pain.
As the cyst enlarges, it can cause noticeable abdominal swelling and problems with the urinary or digestive system.
In more severe cases, individuals might also experience:
The Office on Women’s Health notes that cysts on the ovaries can also cause:
Some potential complications include:
Rupturing of the cyst: Though rare, ovarian dermoid cysts can burst. If the cyst’s contents leak into the abdominal cavity, it may lead to chronic inflammation of the abdominal lining (peritonitis). In some cases, leakage into the intestines or rectum can result in the material being expelled through the anus.
Ovarian torsion: This occurs when the cyst twists the ligaments holding the ovary in place, which can cut off blood supply to the ovary and fallopian tube.
Infection: The risk of infection is around 1–4%. Severe infections may lead to cyst rupture.
Malignant transformation: Dermoid cysts are almost always benign, but in rare instances, they can become cancerous.
Credits: Canva
A new weight-loss drug often described as the “triple G” treatment because it mimics three hormones linked to hunger and metabolism has delivered striking results in fresh data shared Thursday by its developer, Eli Lilly. In a clinical study involving more than 400 people living with obesity and knee osteoarthritis, the experimental drug retatrutide led to an average weight reduction of 71 pounds, or close to 29% of total body weight, over a period of 16 months, according to figures released by the company. Participants who received retatrutide also reported a 76% drop in knee pain by the end of the study period, based on the same data. So is
Retatrutide is an experimental weight-loss drug developed by Eli Lilly and is widely seen as a next-step advancement beyond current GLP-1-based medications such as semaglutide and tirzepatide. While semaglutide acts on a single hormone pathway and tirzepatide works on two, retatrutide targets three.
It activates GLP-1 and GIP, along with an added glucagon pathway, which is why it is sometimes informally referred to as a “GLP-3” drug. Researchers believe this third pathway could explain the greater weight-loss effects seen so far, although retatrutide remains under investigation and has not yet received FDA approval.
Even without regulatory approval, retatrutide has gained attention among gym enthusiasts, fitness creators, and online weight-loss communities. On platforms like TikTok, where direct searches for #reta or #retatrutide are restricted, users often refer to it using coded terms such as “ratatouille.”
At the same time, the drug has been in the news due to growing concerns about counterfeit versions. Reports from the UK recently revealed that authorities seized more than £250,000 worth of fake weight-loss injection pens labelled as tirzepatide and retatrutide from a hidden factory in Northampton. These products are especially concerning because retatrutide is still in clinical trials and has not been approved for use anywhere in the world.
Retatrutide works by mimicking three hormones that play a role in appetite and metabolism: GLP-1, GIP, and glucagon. In contrast, most weight-loss drugs currently available target only one or two of these pathways. Ozempic and Wegovy, made by Novo Nordisk, copy the effects of GLP-1, a hormone that influences the brain, pancreas, stomach, liver, and muscles, according to the National Institutes of Health.
Mounjaro and Zepbound, on the other hand, act on both GLP-1 and GIP, a hormone involved in blood sugar regulation through insulin stimulation. Retatrutide’s added glucagon effect is key, as glucagon is known to support fat burning, even when the body is at rest. Ozempic and Mounjaro are approved by the FDA for treating Type 2 diabetes, while Wegovy and Zepbound are approved for people with overweight or obesity. As with any prescription drug, it is important for individuals to consult a healthcare professional to determine whether these treatments are appropriate for them.
There is currently no confirmed timeline for when retatrutide might become available by prescription. Its launch will depend on the FDA’s detailed evaluation of clinical trial data once it is formally submitted. Based on current expectations, approval is unlikely before late 2026 and could potentially extend into 2027 or even 2028.
© 2024 Bennett, Coleman & Company Limited